a privately held specialty aesthetics company pioneering the development of differentiated medical skincare products based on the science of glycoproteins, announced today the close of a $5 million Series C financing. The newly raised capital will fund expanded sales and marketing operations to broaden the portfolio of Sente physician dispensed medical grade skincare products.
The Series C financing, which included both existing and new individual investors, was led by PharmaBioInvestments Inc., a Durham, NC based investment firm that invests in and assists entrepreneurial life science companies that are developing and marketing products to treat a variety of illnesses.
‘We are very pleased to see a continued strong interest in our company from leading life science investors,’ commented Michael York, President and Chief Executive Officer of Sente, Inc. ‘We remain committed to bringing to market differentiated medical grade skin care products based on our patented low molecular weight heparan sulphate (HS) technology by expanding our portfolio to include three new products by the end of 2014.’
Sente Dermal Repair Cream features a proprietary formulation of low molecular weight HS. Heparan sulphate is the most biologically active of the glycoproteins that reside in all layers of human skin. This biologically active low molecular weight HS analogue used in Sente Dermal Repair Cream helps promote cell renewal, facilitates new collagen development, increases skin hydration, gradually brightens the appearance of pigmented lesions and soothes irritated skin.
‘Sente was established to focus on the science of dermatology and to create proprietary medical grade specialty aesthetic products,’ added Kleanthis G. Xanthopoulos, PhD., Co-Founder and member of the Board of Sente, Inc. ‘We are very happy to have assembled such an outstanding group of investors to help support our mission.’